PTP1B inhibitor alleviates deleterious septic lung injury through Src signaling
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Targeting protein tyrosine phosphatase 1B (PTP1B) offers a novel strategy for treating septic lung injury. Inhibiting PTP1B reduces inflammation and improves outcomes in sepsis models, addressing a critical clinical need.
Area Of Science
- Pulmonary medicine
- Molecular biology
- Immunology
Background
- Septic lung injury presents a significant clinical challenge with high mortality and limited treatment options.
- Uncontrolled pulmonary inflammation is a key factor in sepsis-induced lung injury.
- Targeting early inflammatory responses may offer an effective therapeutic strategy.
Purpose Of The Study
- To investigate the role of PTP1B in septic lung injury.
- To explore the therapeutic potential of PTP1B inhibition in treating sepsis-induced lung injury.
Main Methods
- Established a septic lung injury model using cecal ligation and puncture.
- Utilized Western blotting and immunofluorescence to assess PTP1B, ER stress, and pyroptosis.
- Employed co-immunoprecipitation to analyze PTP1B and Src interactions.
Main Results
- PTP1B expression was upregulated in septic lung injury models (in vivo and in vitro).
- PTP1B directly binds to Src, exacerbating inflammation via the ER stress-pyroptosis pathway.
- PTP1B inhibition ameliorated inflammation and improved survival in septic mice.
Conclusions
- PTP1B plays a critical role in the pathogenesis of septic lung injury by regulating the ER stress-pyroptosis axis.
- PTP1B inhibitors demonstrate potential clinical value for treating septic lung injury.
- Targeting PTP1B represents a promising new therapeutic strategy for this condition.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...